Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Surgery
Erschienen in: Journal of Gastrointestinal Surgery 4/2019

31.01.2019 | Original Article

Natural History and Treatment Trends in Pancreatic Cancer Subtypes

verfasst von: Courtney J. Pokrzywa, Daniel E. Abbott, Kristina A. Matkowskyj, Sean M. Ronnekleiv-Kelly, Emily R. Winslow, Sharon M. Weber, Alexander V. Fisher

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

While pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, many other histologic forms of pancreatic cancer are also recognized. These histologic variants portray unique characteristics in terms of patient demographics, tumor behavior, survival, and responsiveness to treatments.

Materials and Methods

Patients who underwent surgical resection of the pancreas for non-metastatic, invasive pancreatic cancer between 2004 and 2014 were selected from the National Cancer Data Base and categorized by histologic variant according to WHO classification guidelines. Patient demographics, tumor variables, treatment characteristics, and survival were compared between histologic groups and subgroups.

Results

A total of 57,804 patients met inclusion and exclusion criteria and were grouped into eight major histologic categories. Survival analysis by the histologic group showed median overall survival of 20.2 months for ductal adenocarcinoma, 20.5 months for squamous cell carcinoma, 26.8 months for mixed acinar-neuroendocrine carcinomas, 52.6 months for cystic mucinous neoplasms with an associated invasive carcinoma, 67.5 months for acinar cell carcinoma, and 69.3 months for mesenchymal tumors. Median survival was not reached for neuroendocrine tumors and solid-pseudopapillary neoplasms, with 5-year overall survival rates of 84% and 97% respectively.

Conclusions

Rare subtypes of pancreatic cancer present unique clinicopathologic characteristics and display distinct tumor biologies. This study presents data on demographic, prognostic, treatment, and survival outcomes between rare forms of pancreatic neoplasms in order to aid understanding of the natural history and behavior of these neoplasms, with the hope of serving as a reference in clinical decision-making and ability to provide accurate prognostic information to patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Siegel R, Miller K, Jemal A. Cancer Statistics. Ca Cáncer J. 2017;67(1):7–30.CrossRef
2.
Paniccia A, Hosokawa P, Henderson W, Schulick RD, Edil BH, McCarter MD, Gajdos C. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015;150(8):701–710.CrossRefPubMed
3.
Colbert LE, Hall WA, Nickleach D, Switchenko J, Kooby DA, Liu Y, Gillespie T, Lipscomb J, Kauh J, Landry JC. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the national cancer data base. Cancer. 2014;120(4):499–506.CrossRefPubMedPubMedCentral
4.
Åkerberg D, Ansari D, Andersson R. Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol. 2016;22(28):6424–6433.CrossRefPubMedPubMedCentral
5.
Zhou J, Enewold L, Stojadinovic A, Clifton GT, Potter JF, Peoples GE, Zhu K. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control. 2010;21(6):853–861.CrossRefPubMed
6.
Fesinmeyer MD, Austin MA, Li CI, Roos AJ De, Bowen DJ. Differences in Survival by Histologic Type of Pancreatic Cancer Differences in Survival by Histologic Type of Pancreatic Cancer. 2005;14(July):1766–1773.
7.
Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH. Histological Typing of Tumours of the Exocrine Pancreas. Vol 49.; 1996.
8.
Paniccia A, Hosokawa PW, Schulick RD, Henderson W, Kaplan J, Gajdos C. A matched-cohort analysis of 192 pancreatic anaplastic carcinomas and 960 pancreatic adenocarcinomas: A 13-year North American experience using the National Cancer Data Base (NCDB). Surg (United States). 2016;160(2):281–292.PubMed
9.
Raigani S, Ammori J, Kim J, Hardacre JM. Trends in the Treatment of Resectable Pancreatic Adenocarcinoma. J Gastrointest Surg. 2014;18(1):113–123.CrossRefPubMed
10.
Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG, Roman SA, Sosa JA. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. J Surg Oncol. 2017;116(2):127–132.CrossRefPubMed
11.
Shubert CR, Bergquist JR, Groeschl RT, Habermann EB, Wilson PM, Truty MJ, Smoot RL, Kendrick ML, Nagorney DM, Farnell MB. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. Surg (United States). 2016;160(4):1080–1096.PubMed
12.
Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: Analysis of 9,821 patients. J Gastrointest Surg. 2007;11(11):1460–1469.CrossRefPubMed
13.
Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF. Pancreatic neuroendocrine tumors. Cancer. 2009;115(4):741–751.CrossRefPubMed
14.
Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, Xie XJ, Schwarz RE. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol. 2012;105(6):595–600.CrossRefPubMed
15.
Wisnoski NC, Townsend CM, Nealon WH, Freeman JL, Riall TS. 672 Patients With Acinar Cell Carcinoma of the Pancreas: a Population-Based Comparison To Pancreatic Adenocarcinoma. Surgery. 2008;144(2):141–148.CrossRefPubMed
16.
Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol. 2010;34(4):510–518.CrossRefPubMed
17.
Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, Choti MA, Wolfgang CL. Acinar cell carcinoma of the pancreas: An institutional series of resected patients and review of the current literature. J Gastrointest Surg. 2008;12(6):1061–1067.CrossRefPubMed
18.
Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the united states: Prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12(12):2078–2086.CrossRefPubMed
19.
Reddy RP, Smyrk TC, Zapiach M, Levy MJ, Pearson RK, Clain JE, Farnell MB, Sarr MG, Chari ST. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: Demographics, clinical features, and prevalence of cancer. Clin Gastroenterol Hepatol. 2004;2(11):1026–1031.CrossRefPubMed
20.
Crippa S, Salvia R, Warshaw AL, Domínguez I, Bassi C, Falconi M, Thayer SP, Zamboni G, Lauwers GY, Mino-Kenudson M, Capelli P, Pederzoli P, Del Castillo CF. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: Lessons from 163 resected patients. Ann Surg. 2008;247(4):571–579.CrossRefPubMedPubMedCentral
21.
D’Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Analysis of Clinicopathologic Features and Outcome. Ann Surg. 2004;239(3):400–408.CrossRefPubMedPubMedCentral
22.
Gil E, Choi SH, Choi DW, Heo JS, Kim MJ. Mucinous cystic neoplasms of the pancreas with ovarian stroma. ANZ J Surg. 2013;83(12):985–990.CrossRefPubMed
23.
Grützmann R, Niedergethmann M, Pilarsky C, Klöppel G, Saeger HD. Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist. 2010;15(12):1294–1309.CrossRefPubMedPubMedCentral
24.
25.
Nguyen D, Dawson D, Hines J, Reber H, Donahue TR. Mucinous Cystic Neoplasms of the Pancreas : Are We Overestimating Malignant Potential ? Am Surg. 2014;80:915–919.PubMed
26.
Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, Razo O, McGrath D, Pederzoli P, Fernández-Del Castillo C. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology. 2007;133(1):72–9; quiz 309-10.CrossRefPubMedPubMedCentral
27.
Tanaka M, Fernández-Del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–197.CrossRefPubMed
28.
Testini M, Gurrado A, Lissidini G, Venezia P, Greco L, Piccinni G. Management of mucinous cystic neoplasms of the pancreas. World J Gastroenterol. 2010;16(45):5682–5692.CrossRefPubMedPubMedCentral
29.
Wada K, Kozarek RA, Traverso LW, Cook DW. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2005;189(5 SPEC. ISS.):632–637.CrossRefPubMed
30.
Brown H a, Dotto J, Robert M, Salem RR. Squamous Cell Carcinoma of the Pancreas. 2005;39(10):915–919.
31.
Baylor SM, Berg JW. Cross-classification and survival characteristics of 5,000 cases of cancer of the pancreas. J Surg Oncol. 1973;5(4):335–358.CrossRefPubMed
32.
Nakashima H, Hayakawa T, Hoshino M, Kamiya Y, Ohara H, Yamada T, Mizuno K, Inagaki T, Nakazawa T, Yamada H, et al. Squamous cell carcinoma of the pancreas with massive invasion of the retroperitoneum. Intern Med. 1995;34(1):61–64.CrossRefPubMed
33.
Kodavatiganti R, Campbell F, Hashmi A, Gollins SW. Primary squamous cell carcinoma of the pancreas: A case report and review of the literature. J Med Case Rep. 2012;6(1):1. Journal of Medical Case Reports.CrossRef
34.
Ntanasis-Stathopoulos I, Tsilimigras DI, Georgiadou D, Kanavidis P, Riccioni O, Salla C, Psaltopoulou T, Sergentanis TN. Squamous cell carcinoma of the pancreas: A systematic review and pooled survival analysis. Eur J Cancer. 2017;79(2017):193–204.CrossRefPubMed
35.
36.
37.
Kim JY, Song JS, Park H, Byun JH, Song K, Hong S. Primary Mesenchymal Tumors of the Pancreas. 2014;43(6):959–968.
38.
Dai G, Huang L, Du Y, Yang L, Yu P. Solid pseudopapillary neoplasms of the pancreas : clinical analysis of 45 cases. 2015;8(9):11400–11406.
39.
Yang F, Jin C, Long J, Yu XJ, Xu J, Di Y, Li J, Fu DL, Ni QX. Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients. Am J Surg. 2009;198(2):210–215.CrossRefPubMed
40.
Shuja A, Alkimawi K a. Solid pseudopapillary tumor: a rare neoplasm of the pancreas. Gastroenterol Rep. 2014;2(2):145–149.CrossRef
41.
Chang MK, Kyung SK, Jin SC, Kim H, Woo JL, Byong RK. Solid pseudopapillary tumor of the pancreas suggesting malignant potential. Pancreas. 2006;32(3):276–280.CrossRef
42.
de Castro SM, Singhal D, Aronson DC, Busch OR, van Gulik TM, Obertop H, Gouma DJ. Management of solid-pseudopapillary neoplasms of the pancreas: a comparison with standard pancreatic neoplasms. World J Surg. 2007;31(5):1130–1135.CrossRefPubMedPubMedCentral
43.
Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, DeMarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA. Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas Are Genetically Similar and Distinct from Well- differentiated Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2012;36(2):173–184.CrossRefPubMedPubMedCentral
44.
Goh BKP, Tan YM, Cheow PC, Chung YFA, Chow PKH, Wong WK, Ooi LLPJ. Solid pseudopapillary neoplasms of the pancreas: An updated experience. Journal of Surgical Oncology. Vol 95. ; 2007:640–644.CrossRefPubMed
45.
Ohike N, Kosmahl M, Klöppel G. Mixed acinar-endocrine carcinoma of the pancreas. A clinicopathological study and comparison with acinar-cell carcinoma. Virchows Arch. 2004;445(3):231–235.CrossRefPubMed
46.
Ogbonna OH, Garcon MC, Syrigos KN, Saif MW. Mixed acinar-neuroendocrine carcinoma of the pancreas with neuroendocrine predominance. Case Rep Med. 2013;2013(grade 3):10–13.
47.
Klimstra DS, Rosai J, Heffess CS. Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol. 1994;18(8):765–778.CrossRefPubMed
48.
Kyriazi MA, Arkadopoulos N, Stafyla VK, Yiallourou AI, Dafnios N, Theodosopoulos T, Kairi-Vassilatou E, Smyrniotis V. Mixed acinar-endocrine carcinoma of the pancreas: A case report and review of the literature. Cases J. 2009;2(4):1–5.
49.
Boman FT, Carneiro F, Hruban RH TN. WHO Classification of Tumours of the Digestive System, 4th edn. Fr IARC. 2010.
50.
Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernández-del Castillo C, Lillemoe KD, Warshaw AL. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152(3 Suppl 1):S43–9.CrossRefPubMedPubMedCentral
51.
Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586–594.CrossRefPubMed
52.
Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PWT, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60.CrossRefPubMedPubMedCentral
53.
Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic adenocarcinoma: The actual 5-year survivors. J Gastrointest Surg. 2008;12(4):701–706.CrossRefPubMed
54.
Sho M, Murakami Y, Motoi F, Satoi S, Matsumoto I, Kawai M, Honda G, Uemura K, Yanagimoto H, Kurata M, Fukumoto T, Akahori T, Kinoshita S, Nagai M, Nishiwada S, Unno M, Yamaue H, Nakajima Y. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: A multicenter study on 822 patients. J Gastroenterol. 2015;50(6):694–702.CrossRefPubMed
55.
Ahmad N a, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, Rosato EF, Kochman ML. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol. 2001;96(9):2609–2615.CrossRef
56.
Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, MacKenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S. Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg. 2004;198(5):722–731.CrossRefPubMed
57.
Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, Johung KL. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base. Cancer. 2015;121(23):4141–4149.CrossRefPubMed
58.
Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman JA, Sauter PK, Pitt HA, Lilltemoe KD, Cameron JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival: A prospective, single-institution experience. Ann Surg. 1997;225(5):621–636.CrossRefPubMedPubMedCentral
59.
Nitecki SS, Sarr MG, Colby T V, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221(1):59–66.CrossRefPubMedPubMedCentral
60.
Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma is cure possible? Ann Surg. 2008;247(3):456–462.CrossRefPubMed
61.
Donahue TR, Reber HA. Surgical management of pancreatic cancer - Pancreaticoduodenectomy. Semin Oncol. 2015;42(1):98–109.CrossRefPubMed
62.
Kuhlmann KFD, De Castro SMM, Wesseling JG, Ten Kate FJW, Offerhaus GJA, Busch ORC, Van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma: Actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40(4):549–558.CrossRefPubMed
63.
Liu Z, Dong C, Wang C, Liu Q, Sun D, Wang L. Mixed acinar-endocrine carcinoma of pancreas: A case report and brief review of the literature. Onco Targets Ther. 2015;8:1633–1642.CrossRefPubMedPubMedCentral
64.
Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: A population-based analysis of prognosis and survival. J Surg Res. 2012;174(1):12–19.CrossRefPubMed
65.
Imaoka H, Shimizu Y, Mizuno N, Hara K, Hijioka S, Tajika M, Kondo S, Tanaka T, Ogura T, Obayashi T, Hasegawa T, Niwa Y, Yamao K. Clinical characteristics of adenosquamous carcinoma of the pancreas: A matched case-control study. Pancreas. 2014;43(2):287–290.CrossRefPubMed
66.
Clancy TE. Surgical Management of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30(1):103–118.CrossRefPubMed
67.
Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: Current concepts and controversies. Endocr Pathol. 2014;25(1):65–79.CrossRefPubMed
68.
Wang Y, Wang S, Zhou X, Zhou H, Cui Y, Li Q, Zhang L. Acinar cell carcinoma: A report of 19 cases with a brief review of the literature. World J Surg Oncol. 2016;14(1):1–8.CrossRef
69.
Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, Merchant N, Johnson CS, Lillemoe KD, Grützmann R. Pancreatic acinar cell carcinoma: A multi-institutional study. J Gastrointest Surg. 2009;13(8):1495–1502.CrossRefPubMed
70.
Lowery MA, Klimstra DS, Shia J, Yu KH, Allen PJ, Brennan MF, O’Reilly EM. Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. Oncologist. 2011;16(12):1714–1720.CrossRefPubMedPubMedCentral
71.
Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, Thoburn K, Gress D, McKellar DP, Shulman LN, Facktor MA, Winchester DP. Using the National Cancer Database for Outcomes Research. JAMA Oncol. 2017.
72.
Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol. 2013.
Metadaten
Titel
Natural History and Treatment Trends in Pancreatic Cancer Subtypes
verfasst von
Courtney J. Pokrzywa
Daniel E. Abbott
Kristina A. Matkowskyj
Sean M. Ronnekleiv-Kelly
Emily R. Winslow
Sharon M. Weber
Alexander V. Fisher
Publikationsdatum
31.01.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 4/2019
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04113-3

Weitere Artikel der Ausgabe 4/2019

Journal of Gastrointestinal Surgery 4/2019 Zur Ausgabe

Original Article

Long-term Outcomes After Surgery Involving the Pelvic Floor in Rectal Cancer: Physical Activity, Quality of Life, and Health Status

2018 SSAT Quick Shot Presentation

The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma

Original Article

Utility of Image Guidance in the Localization of Disappearing Colorectal Liver Metastases

2018 SSAT Plenary Presentation

Timing and Outcomes of Abdominal Surgery in Neutropenic Patients

Multimedia Article

Pure Laparoscopic Right Posterior Sectionectomy Using the Glissonean Approach and a Modified Liver Hanging Maneuver (Video)

GI Image

Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.